Anthony Petrone
Stock Analyst at Mizuho
(4.13)
# 470
Out of 5,156 analysts
218
Total ratings
56.25%
Success rate
10.96%
Average return
Main Sectors:
Stocks Rated by Anthony Petrone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LNTH Lantheus Holdings | Maintains: Outperform | $72 → $85 | $80.01 | +6.24% | 8 | Feb 27, 2026 | |
| ESTA Establishment Labs Holdings | Maintains: Outperform | $90 → $100 | $69.06 | +44.80% | 10 | Feb 25, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $21 → $22 | $20.88 | +5.36% | 3 | Feb 20, 2026 | |
| DXCM DexCom | Maintains: Outperform | $78 → $90 | $68.74 | +30.93% | 4 | Feb 13, 2026 | |
| INSP Inspire Medical Systems | Maintains: Outperform | $130 → $85 | $61.89 | +37.34% | 8 | Feb 12, 2026 | |
| HAE Haemonetics | Maintains: Outperform | $90 → $80 | $64.23 | +24.55% | 17 | Feb 6, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $140 → $115 | $71.90 | +59.94% | 9 | Feb 5, 2026 | |
| EXAS Exact Sciences | Downgrades: Neutral | $85 → $105 | $103.71 | +1.24% | 2 | Jan 20, 2026 | |
| MDXG MiMedx Group | Maintains: Outperform | $12 → $10 | $4.51 | +121.73% | 5 | Dec 17, 2025 | |
| LIVN LivaNova | Maintains: Outperform | $70 → $72 | $62.06 | +16.02% | 10 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $120 | $91.20 | +31.58% | 4 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $100 | $75.82 | +31.89% | 16 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $29.28 | +36.61% | 1 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $100 | $81.85 | +22.17% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $300 | $252.93 | +18.61% | 18 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $100 | $84.26 | +18.68% | 10 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $70 → $78 | $75.59 | +3.19% | 10 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $130 → $135 | $113.61 | +18.83% | 9 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $140 → $135 | $112.65 | +19.84% | 6 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $18.32 | -1.75% | 8 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $98 → $100 | $91.34 | +9.48% | 7 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $12 | $9.23 | +30.01% | 3 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $175 | $105.78 | +65.44% | 10 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $6.31 | +533.91% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $58 | $74.49 | -22.14% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $14 | $15.81 | -11.45% | 6 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $105 | $75.63 | +38.83% | 6 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $350 → $390 | $493.56 | -20.98% | 6 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $63 → $67 | $110.07 | -39.13% | 2 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $175 | $93.28 | +87.61% | 3 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $25 | $11.40 | +119.30% | 3 | May 13, 2020 |
Lantheus Holdings
Feb 27, 2026
Maintains: Outperform
Price Target: $72 → $85
Current: $80.01
Upside: +6.24%
Establishment Labs Holdings
Feb 25, 2026
Maintains: Outperform
Price Target: $90 → $100
Current: $69.06
Upside: +44.80%
Tandem Diabetes Care
Feb 20, 2026
Maintains: Neutral
Price Target: $21 → $22
Current: $20.88
Upside: +5.36%
DexCom
Feb 13, 2026
Maintains: Outperform
Price Target: $78 → $90
Current: $68.74
Upside: +30.93%
Inspire Medical Systems
Feb 12, 2026
Maintains: Outperform
Price Target: $130 → $85
Current: $61.89
Upside: +37.34%
Haemonetics
Feb 6, 2026
Maintains: Outperform
Price Target: $90 → $80
Current: $64.23
Upside: +24.55%
Boston Scientific
Feb 5, 2026
Maintains: Outperform
Price Target: $140 → $115
Current: $71.90
Upside: +59.94%
Exact Sciences
Jan 20, 2026
Downgrades: Neutral
Price Target: $85 → $105
Current: $103.71
Upside: +1.24%
MiMedx Group
Dec 17, 2025
Maintains: Outperform
Price Target: $12 → $10
Current: $4.51
Upside: +121.73%
LivaNova
Dec 17, 2025
Maintains: Outperform
Price Target: $70 → $72
Current: $62.06
Upside: +16.02%
Dec 17, 2025
Maintains: Outperform
Price Target: $100 → $120
Current: $91.20
Upside: +31.58%
Dec 5, 2025
Maintains: Outperform
Price Target: $85 → $100
Current: $75.82
Upside: +31.89%
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $29.28
Upside: +36.61%
Nov 11, 2025
Maintains: Outperform
Price Target: $110 → $100
Current: $81.85
Upside: +22.17%
Oct 31, 2025
Maintains: Outperform
Price Target: $310 → $300
Current: $252.93
Upside: +18.61%
Oct 31, 2025
Maintains: Outperform
Price Target: $90 → $100
Current: $84.26
Upside: +18.68%
Oct 23, 2025
Downgrades: Neutral
Price Target: $70 → $78
Current: $75.59
Upside: +3.19%
Aug 1, 2025
Maintains: Neutral
Price Target: $130 → $135
Current: $113.61
Upside: +18.83%
Jul 18, 2025
Maintains: Neutral
Price Target: $140 → $135
Current: $112.65
Upside: +19.84%
Jul 16, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $18.32
Upside: -1.75%
Jul 16, 2025
Maintains: Outperform
Price Target: $98 → $100
Current: $91.34
Upside: +9.48%
Jul 16, 2025
Maintains: Neutral
Price Target: $13 → $12
Current: $9.23
Upside: +30.01%
Apr 16, 2025
Maintains: Outperform
Price Target: $200 → $175
Current: $105.78
Upside: +65.44%
Apr 10, 2025
Initiates: Outperform
Price Target: $40
Current: $6.31
Upside: +533.91%
Mar 6, 2025
Maintains: Buy
Price Target: $54 → $58
Current: $74.49
Upside: -22.14%
Jun 20, 2024
Maintains: Buy
Price Target: $12 → $14
Current: $15.81
Upside: -11.45%
May 1, 2024
Maintains: Buy
Price Target: $110 → $105
Current: $75.63
Upside: +38.83%
Jan 25, 2024
Maintains: Neutral
Price Target: $350 → $390
Current: $493.56
Upside: -20.98%
Aug 3, 2023
Downgrades: Hold
Price Target: $63 → $67
Current: $110.07
Upside: -39.13%
Nov 5, 2021
Maintains: Buy
Price Target: $200 → $175
Current: $93.28
Upside: +87.61%
May 13, 2020
Maintains: Hold
Price Target: $30 → $25
Current: $11.40
Upside: +119.30%